Concepedia
Statistics
Publications
9
Citations
480
H-Index
Active since
2011
Affiliations
Pfizer (United States)(Current)
Pfizer (Ireland)
Nanotherapeutics (United States)
Amy King is an author at Pfizer (United States) specializing in pharmacy, antibody engineering, and antibody discovery.
Publications per year
2011–2021
Establishing <i>in vitro in vivo</i> correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics
Lindsay B. Avery, Jason Wade, Mengmeng Wang et al. · mAbs · 2017 · 102 citations · Full text
Pharmacy, Pharmacokinetics, Pharmacology +17
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Wei Cao, Bilian Li, Peter LaPan et al. · Antibodies · 2016 · 95 citations · Full text
Pharmacy, Immunology, Medicinal Chemistry +17
Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics
Nicole Piche‐Nicholas, Lindsay B. Avery, Amy King et al. · mAbs · 2017 · 75 citations · Full text
Medicine, Pharmacokinetics, Pharmacology +17
High‐throughput measurement, correlation analysis, and machine‐learning predictions for pH and thermal stabilities of Pfizer‐generated antibodies
Amy King, Matthew Woods, Wei Liu et al. · Protein Science · 2011 · 66 citations · Full text
Life Sciences, Biochemistry, Molecular Biology +16
Modeling and mitigation of high-concentration antibody viscosity through structure-based computer-aided protein design
James R. Apgar, Amy Tam, Rhady Sorm et al. · PLoS ONE · 2020 · 52 citations · Full text
Pharmacy, Bioengineering, Pharmaceutics +17
1–5 of 9